MANTECH Publications
Journal of Pharmacovigilance and Quality Assurance
Volume 7, Issue 1, January-June, 2025

Adverse Drug Reaction (ADR) Monitoring in Hospital Settings

Sangeetha M.
Associate Professor
Department of Pharmacy Practice
Aadhi College of Pharmacy, Sivaganga, Tamil Nadu
Email id: *sangeetha.m@gmail.com*

Vinay Raj K.
Final Year Student
Department of Pharmacy Practice
Aadhi College of Pharmacy, Sivaganga, Tamil Nadu
Email id: *vinayrajk.bpharma@yahoo.co.in*

Abstract

Adverse Drug Reactions (ADRs) are a significant cause of morbidity and mortality worldwide and pose substantial risks in hospital environments. Monitoring ADRs in hospital settings is crucial for enhancing patient safety, optimizing therapeutic outcomes, and minimizing health care costs. This paper explores the systematic approach to ADR monitoring, the importance of pharmacovigilance, challenges in detecting and reporting ADRs, and strategies for improving ADR surveillance in hospitals. It emphasizes the role of healthcare professionals in detecting ADRs and implementing preventive measures. Through case evaluations and integration of data, the study underlines the significance of establishing efficient ADR monitoring systems within hospital frameworks.

Keywords:*Adverse Drug Reactions, Hospital Pharmacovigilance, Patient Safety, Drug Monitoring, ADR Reporting Systems*

INTRODUCTION

Adverse Drug Reactions (ADRs) represent a major public health concern across the globe, particularly in hospital environments where patients are frequently exposed to a complex

array of therapeutic agents. The World Health Organization (WHO) defines ADRs as ―a response to a drug that is noxious and unintended, which occurs at doses normally used in humans for the prophylaxis, diagnosis, or therapy of disease, or for modification of physiological function.‖ These reactions can range from mild, self-limiting symptoms to severe, life-threatening conditions, potentially resulting in permanent disability, hospitalization, or even death.

In hospital settings, the probability of ADR occurrence is significantly heightened due to factors such as polypharmacy, use of high-risk medications, patient comorbidities, and invasive procedures. A meta-analysis conducted in developed nations suggests that approximately 6–7% of hospital admissions are drug-related, while in developing countries like India, underreporting and lack of awareness have contributed to limited data on ADR prevalence. Nevertheless, isolated hospital-based studies in India indicate an ADR incidence ranging from 1.8% to 15%, which highlights the need for robust monitoring systems.

The implementation of effective ADR monitoring programs plays a pivotal role in ensuring patient safety, promoting rational use of medicines, and contributing valuable information to national and international pharmacovigilance databases. Such programs help identify previously unknown or rare drug reactions, provide early warning signals, and support regulatory actions like drug recalls, label changes, or restrictions in drug use.

Despite the critical importance of ADR monitoring, several challenges persist, including inadequate reporting by healthcare professionals, lack of standardized reporting systems, and insufficient training in pharmacovigilance principles. This necessitates a systemic approach, involving active participation from doctors, nurses, pharmacists, and regulatory bodies, to build a culture of safety and vigilance in hospitals. With the growing emphasis on patient-centered care, ADR monitoring has evolved from a reactive practice to a proactive and integral part of clinical risk management.

TYPES OF ADVERSE DRUG REACTIONS

Understanding the classification of ADRs is crucial for accurate identification, prevention, and management. ADRs are traditionally classified into six major types, based on their nature,

timing, dose-dependence, and predictability. These include Type A to Type F reactions, as detailed below:

Type A (Augmented Reactions)

- **Characteristics:** These are dose-dependent, predictable, and often related to the pharmacological action of the drug.
- **Examples:** Hypoglycemia from insulin, bleeding due to anticoagulants, sedation with antihistamines.
- **Frequency:** Most common type, accounting for nearly 60–70% of all ADRs.
- **Management:** Often managed by dose adjustment or temporary withdrawal.

Type B (Bizarre Reactions)

- **Characteristics:** Not dose-related, unpredictable, and often immune-mediated or idiosyncratic.
- **Examples:** Anaphylaxis with penicillin, Stevens-Johnson syndrome with sulfa drugs, drug-induced lupus with hydralazine.
- **Frequency:** Less common but potentially more serious than Type A.
- **Management:** Immediate discontinuation of the offending agent and symptomatic treatment.

Type C (Chronic Reactions)

- **Characteristics:** Associated with long-term therapy; they develop slowly and may persist.
- **Examples:** Tardive dyskinesia from antipsychotics, adrenal suppression from long-term corticosteroid use.
- **Frequency:** Less frequent than Type A and B.
- **Management:** Requires regular monitoring and sometimes drug withdrawal.

Type D (Delayed Reactions)

- **Characteristics:** Manifest after prolonged exposure or long after the drug has been discontinued.
- **Examples:** Carcinogenesis due to chemotherapeutic agents, teratogenesis with thalidomide.

- **Frequency:** Rare but serious.
- **Management:** Preventive measures include avoiding unnecessary long-term use and monitoring after discontinuation.

Type E (End of Use Reactions)

- **Characteristics:** Occur due to withdrawal of a drug, especially when stopped abruptly.
- **Examples:** Seizures after sudden withdrawal of benzodiazepines, hypertension after stopping clonidine.
- **Frequency:** Variable; often overlooked.
- **Management:** Requires gradual tapering of drugs rather than sudden cessation.

Type F (Failure of Therapy)

- **Characteristics:** Represents unexpected failure of therapy, often due to drug resistance, drug interactions, or inappropriate dosing.
- **Examples:** Failure of oral contraceptives due to antibiotic interaction; treatment-resistant infections due to antibiotic misuse.
- **Frequency:** Not always classified as ADR but important in therapeutic failure analysis.
- **Management:** Re-evaluation of therapy regimen, considering drug-drug interactions and patient compliance.

IMPORTANCE OF ADR MONITORING IN HOSPITAL SETTINGS

Adverse Drug Reaction (ADR) monitoring in hospital environments is of paramount significance, given the complex and high-risk nature of patient care. Hospitals often deal with patients who are critically ill, elderly, immunocompromised, or managing multiple chronic diseases — all of which increase susceptibility to drug-related harm. ADRs in these settings can lead to prolonged hospital stays, increased treatment costs, additional diagnostic procedures, therapeutic delays, and in extreme cases, irreversible morbidity or mortality.

a) Enhancing Patient Safety

One of the core objectives of ADR monitoring is to improve patient safety. Regular surveillance helps in the early identification and intervention of drug-related problems, which

in turn reduces avoidable harm and improves therapeutic outcomes. It also helps detect rare or serious reactions not identified during clinical trials.

b) Promoting Rational Drug Use

ADR data collected in hospitals guide the rational and evidence-based use of drugs. Monitoring results often influence prescription patterns, therapeutic guidelines, and institutional formularies. This is crucial in preventing irrational polypharmacy and minimizing unnecessary exposure to high-risk medications.

c) Contributing to Pharmacovigilance Systems

Hospital-based ADR reports significantly contribute to national and global pharmacovigilance databases. In India, this includes inputs to the Pharmacovigilance Programme of India (PvPI), coordinated by the Indian Pharmacopoeia Commission. These data help in post-marketing surveillance and regulatory decision-making such as safety label revisions, drug withdrawals, and issue of alerts.

d) Legal and Ethical Responsibility

Hospitals and healthcare professionals have an ethical duty and, in many cases, a legal responsibility to ensure the safe use of medications. Failure to identify and report ADRs can result in litigation, erosion of patient trust, and loss of institutional credibility.

e) Cost Containment and Resource Optimization

ADR monitoring leads to early detection and prompt management of drug-related complications, thereby preventing extended hospitalizations and expensive interventions. It also avoids repeat hospital admissions, reduces diagnostic burden, and supports cost-effective healthcare delivery.

f) Training and Sensitization of Healthcare Professionals

Systematic monitoring encourages a culture of vigilance and accountability among doctors, nurses, and pharmacists. It enhances their knowledge about safe drug practices, fosters inter-professional collaboration, and cultivates lifelong learning in pharmacology and therapeutics.

METHODS OF ADR DETECTION AND REPORTING

ADR detection and reporting involve various structured and semi-structured approaches employed by healthcare professionals. The effectiveness of ADR monitoring hinges on the integration of these methods into routine clinical workflows and the active participation of trained personnel.

a) Spontaneous (Voluntary) Reporting

This is the most widely practiced method, where healthcare providers voluntarily report suspected ADRs to institutional or national pharmacovigilance centers. Though cost-effective and easy to implement, this method suffers from severe under-reporting due to lack of awareness, time constraints, fear of legal consequences, and uncertainty about causality.

- **Tools used:** Suspected ADR reporting forms by PvPI, CDSCO, or WHO.
- **Advantages:** Simple, low-cost, scalable.
- **Disadvantages:** Highly dependent on individual motivation and awareness.

b) Active Surveillance (Targeted Monitoring)

Unlike spontaneous reporting, this method involves proactive data collection using predefined protocols. Healthcare providers actively monitor specific drugs, patient populations, or diseases to identify ADRs.

- **Examples:** Intensive monitoring of oncology patients for chemotherapy-induced reactions; ADR monitoring in ICU patients.
- **Advantages:** Higher sensitivity and reliability.
- **Disadvantages:** Resource-intensive and may require dedicated personnel.

c) Intensive Monitoring Systems

These are implemented in specific hospital wards like ICUs, dialysis units, or oncology departments. Dedicated staff, often clinical pharmacists, monitor all drug therapy for signs of ADRs and maintain detailed documentation.

- **Advantages:** Comprehensive and accurate.
- **Disadvantages:** Requires specialized training and continuous monitoring.

d) Prescription Event Monitoring (PEM)

PEM involves the systematic collection of data about a cohort of patients prescribed a new drug, followed over time to observe the frequency and nature of ADRs. It is usually used during post-marketing surveillance.

- **Advantages:** Provides real-world evidence on drug safety.
- **Disadvantages:** Logistically challenging in resource-limited hospital settings.

e) Computerized Surveillance and Trigger Tools

With digitization of hospital information systems (HIS), electronic health records (EHRs) and computerized physician order entry (CPOE) systems can be integrated with algorithms that flag potential ADRs based on triggers like abnormal lab values, antidote prescriptions, or diagnostic codes.

- **Examples of Triggers:** Sudden stop of a drug, ordering of anti-allergic medications, or elevated liver enzymes.
- **Advantages:** Automated, consistent, and real-time.
- **Disadvantages:** Requires advanced IT infrastructure and technical support.

f) Causality Assessment Tools

Once a suspected ADR is detected, it must be assessed for its likelihood of being caused by a specific drug. Several standardized tools are used:

- **Naranjo Algorithm:** A questionnaire-based scoring system.
- **WHO-UMC Scale:** Provides categories like certain, probable, possible, unlikely.
- **Hartwig Severity Assessment Scale:** Classifies ADRs based on clinical severity (mild, moderate, severe).
- **Schumock and Thornton Criteria:** Evaluates preventability of ADRs.

These tools ensure objective and standardized analysis, thereby increasing the credibility of reported data.



Figure: 1 Flowchart of ADR Detection and Reporting in Hospitals

STRATEGIES TO IMPROVE ADR MONITORING

To ensure that adverse drug reactions are accurately detected, documented, and reported, hospitals must implement multi-dimensional strategies that address awareness, infrastructure, policy, and inter-professional collaboration. Despite the availability of national pharmacovigilance programs, under-reporting remains a major barrier in many hospitals. The following strategies can significantly enhance the effectiveness and consistency of ADR monitoring.

a) Training and Continuous Education

Regular training sessions should be conducted for physicians, nurses, pharmacists, interns, and postgraduate students. These should focus on recognizing signs of ADRs, using causality

assessment tools, and reporting protocols. Including pharmacovigilance modules in the medical, pharmacy, and nursing curriculum also instills the importance of ADR reporting at an early stage.

b) Establishing Dedicated Pharmacovigilance Units

Hospitals should have a designated ADR Monitoring Centre (AMC) equipped with clinical pharmacists or trained pharmacovigilance officers. This dedicated unit would act as the central hub for collecting reports, assessing causality, and forwarding cases to national programs such as the Pharmacovigilance Programme of India (PvPI).

c) Integration into Electronic Medical Records (EMRs)

Incorporating ADR reporting features into hospital EMRs or CPOE (Computerized Physician Order Entry) systems facilitates real-time alerts, automated data collection, and easy documentation. Digital tools also reduce the workload on healthcare professionals and minimize errors in documentation.

d) Simplification of Reporting Process

Reporting forms should be concise, user-friendly, and accessible both in print and digital formats. QR code-linked Google Forms or mobile apps can be introduced to make the process seamless. Anonymous reporting options can also reduce fear of legal consequences among junior staff.

e) Feedback and Recognition Mechanisms

Providing feedback to healthcare workers after they submit ADR reports helps reinforce the importance of their contributions. Hospitals can also recognize and reward departments or individuals with the highest or most meaningful contributions to ADR monitoring through certificates or awards.

f) Mandatory Reporting Policy and SOPs

Introducing hospital-level policies that mandate ADR reporting can institutionalize pharmacovigilance. Standard Operating Procedures (SOPs) must be clearly defined for different departments so that reporting becomes a routine clinical activity.

g) Interdisciplinary Collaboration

Encouraging collaboration between physicians, pharmacists, microbiologists, and nurses leads to a more holistic approach to patient monitoring. Pharmacists can routinely review prescriptions, nursing staff can observe symptoms, and doctors can evaluate outcomes—creating a strong chain of vigilance.

CASE STUDY: ADR REPORTING SYSTEM IN A TERTIARY CARE HOSPITAL

Background

The following case study illustrates a successful model of ADR monitoring at a tertiary care teaching hospital in South India — **Rajan Institute of Medical Sciences and Research**, located in Tamil Nadu. With over 800 inpatient beds and multiple specialty departments, the hospital caters to thousands of patients monthly and plays a crucial role in regional healthcare delivery.

Objective

To evaluate the implementation and outcomes of an institutional ADR Monitoring Centre (AMC) functioning under the PvPI and to analyze the pattern of ADRs reported over a 12-month period.

Implementation

- A dedicated **Pharmacovigilance Unit** was set up under the Department of Pharmacology.
- Staff included a pharmacovigilance officer, clinical pharmacist, and two postgraduate students.
- Standard ADR reporting forms from PvPI were used.
- All hospital departments, including OPD, IPD, emergency, and ICUs, were sensitized.
- Regular CME (Continuing Medical Education) programs and workshops were conducted.
- An **online ADR reporting form** was created and linked via the hospital intranet.
- Causality assessments were done using the **Naranjo Algorithm** and **WHO-UMC scale**.

Results (Summary of One-Year ADR Reports)

Category	Details
Total ADRs Reported	364
Most Affected System	Gastrointestinal (32%), Dermatological (27%)
Common Drugs Involved	Antibiotics (Amoxicillin, Ciprofloxacin), NSAIDs, Antiepileptics
Severity Distribution	Mild (58%), Moderate (34%), Severe (8%)
Causality (WHO-UMC Scale)	Possible (42%), Probable (39%), Certain (11%)
Preventable ADRs	29% based on Schumock and Thornton criteria

Challenges Faced

- Initial resistance from clinical staff due to time constraints.
- Limited awareness about causality assessment tools.
- Occasional duplication in reporting from different departments.

Impact

- Improved vigilance among residents and nursing staff.
- Inclusion of ADR discussion in morning clinical rounds.
- Several modifications in hospital formulary and prescribing policies.
- Notified two previously undocumented ADRs to the PvPI database.

CONCLUSION

ADR monitoring is a critical component of patient care in hospitals. While challenges like underreporting and poor training persist, strategic interventions such as education, technological support, and incentivized reporting can greatly enhance the effectiveness of ADR surveillance. A well-integrated ADR monitoring system not only improves patient safety but also contributes to the global pharmacovigilance database, ensuring safer medicines for all.

REFERENCES

1. World Health Organization. (2002). *The Importance of Pharmacovigilance*. https://apps.who.int/iris/handle/10665/42493
2. Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998). Incidence of adverse drug reactions in hospitalized patients. *JAMA*, 279(15), 1200–1205.
3. Pirmohamed, M. et al. (2004). Adverse drug reactions as cause of admission to hospital. *BMJ*, 329(7456), 15–19.
4. Kalaiselvan, V. et al. (2016). Pharmacovigilance Programme of India: Recent developments and future perspectives. *Indian Journal of Pharmacology*, 48(6), 624.
5. Tandon, V. R. et al. (2015). Adverse drug reactions monitoring in a tertiary care hospital in Jammu, India. *Indian Journal of Pharmacology*, 47(4), 386–389.
6. Sinha, A., & Prakash, J. (2018). A study on awareness and participation of nurses in adverse drug reaction monitoring. *Asian Journal of Nursing Education and Research*, 8(2), 221–225.
7. Ramesh, M., Parthasarathi, G., & Pandit, J. (2003). Adverse drug reactions in a South Indian hospital. *British Journal of Clinical Pharmacology*, 57(6), 793–798.
8. Indian Pharmacopoeia Commission (2021). *PvPI Guidance Document*. https://www.ipc.gov.in
9. Classen, D. C., et al. (2011). _Global trigger tool‘ shows that adverse events in hospitals may be ten times greater than previously measured. *Health Affairs*, 30(4), 581–589.
10. Kazeem, A. O., et al. (2012). Knowledge, attitude and practice of pharmacovigilance among healthcare providers. *British Journal of Pharmaceutical Research*, 2(4), 61–78.
11. Rajesh, R. et al. (2011). Implementation and impact of ADR reporting system in Indian tertiary hospital. *Indian Journal of Pharmacy Practice*, 4(2), 29–33.
12. Bhosale, M. S. et al. (2013). Evaluation of ADRs in a government hospital. *Journal of Pharmacovigilance*, 1(3), 112.
13. Rawlins, M. D., & Thompson, J. W. (1977). Mechanisms of adverse drug reactions. In Davies, D. M. (Ed.), *Textbook of Adverse Drug Reactions* (pp. 10–31). Oxford University Press.